A CAGR of 6.53% is projected for the influenza vaccines market by 2025, reaching USD 7,828.3 Million. Humans are susceptible to the influenza virus, a very common and deadly virus that can infect their respiratory systems. A respiratory illness caused by a virus, influenza affects the lungs, nose, and throat. Chronically ill people and those with weak immune systems are at the greatest risk. A viral infection that causes oozing from the nose and lungs spreads from person to person.
Vaccines reduce infections by enhancing the body's natural defense. Vaccines increase the body's production of antibodies to fight diseases. The vaccine protects against most diseases for several years, decades, or possibly even a lifetime. Most widely available in the influenza vaccines market are two different influenza vaccine types; these are the inactivated influenza vaccine (IIV) and the live attenuated influenza vaccine (LAIV). Both of these vaccines have three different seasonal protection properties. Vaccinations are the most effective method of preventing influenza viruses from spreading to humans.
It is forecasted that the influenza vaccine market size will strike up to $6.20 Billion in 2026. In 2018, it is projected that the influenza vaccine market size will be $3.96 Billion, with a 5.9% (CAGR) rise in the annual growth rate from 2019 to 2026. Between 2019 to 2020, the static data from the centers for disease control and prevention reports the documented flu cases of over 13 million. A licensed seasonal vaccine is recommended by government organizations, the Center for Disease Control, and the World Health Organization depending on the current market situation of influenza vaccines. Big giants and organizations dealing in pharmaceuticals are putting in continuous efforts to improvise the effects of vaccines against varied infections caused through influenza which has, in turn, led to an upsurge in the influenza vaccine market value.
A market analysis report on the influenza vaccines market and its competitive strength are presented in this report. Furthermore, the report covers key factors such as dynamics, segmentation, key players, and regional analysis. It featured a comprehensive analysis of influenza vaccines worldwide and forecasts through 2025.
COVID 19 Analysis
The influenza vaccines market size has bolstered the development of the rising vaccinations demand. Globally, the pandemic has affected the flu vaccine market tremendously; this has affected the market for influenza vaccines. As a result of the effectiveness of vaccines in deterring diseases and infections worldwide, demand for vaccines is on the rise. Pfizer released a report at the beginning of 2020. The news that Covid 19 vaccines have been released has indeed raised the value of the influenza vaccine market, despite no disruptions occurring in the supply chains.
The experts from Brazil suggest that before the inception of covid death rates can be reduced by 20% with the vaccine shot and after the inception of covid vaccine the death rates can be lessened by 27%. In her view, these factors can toss the demand for this influenza vaccine.
Recent years have seen a tremendous jump in sales of influenza vaccines. Several factors are contributing to the increased market value, such as the heightened awareness of the disease among the people, funding, and the fear of an influenza pandemic.
UK, France, Germany, United States, Japan, Spain, and Italy are among seven markets with a strong annual growth rate of 126.5%.
In 2018, the influenza virus was detected in 69,009 people, 67,733 of which had influenza A virus and the rest influenza B virus. There were 49.0 million cases of influenza infection in 2010 in the United States, up from 9.2 million cases in 2009.
Children 6 months and older are most likely to receive the inactivated influenza vaccine (IIV). Adults or people who are 18 and older are the only people who can receive the recombinant influenza vaccine. For people aged 65 years, it has been advised that adjuvant vaccines consume the highest doses.
With the help of influenza vaccines, the government has assured the well-being of the citizens by reducing the side effects. The upwards trend in the influenza vaccine market is seen because of the creation of new vaccines and improvement of the current ones.
The population has also lifted up and major companies are investing and expanding in the influenza vaccine market growth.
With the advent of the novel covid-19 virus and several other seasons, the influenza vaccines market is under pressure and experiencing challenges and obstacles. The best time frame of production, development, and shipping of vaccines is 6 months. If vaccines aren't manufactured on time, influenza vaccines market share and revenue are likely to be lost.
According to the manufacturers, a variety of influenza types, vaccine types, manufacturing technology, and end-users present four different segments within the influenza vaccine market. Vaccines against influenza have been classified into zoonotic and seasonal types based on the type. Additionally, vaccines have been categorized based on manufacturing technology, such as egg-based vaccines, cell-culture-based vaccines, and recombinant-based vaccines. Types of vaccines include trivalent vaccines and quadrivalent vaccines.
The influenza vaccine market is segmented based on the end-users and applications of influenza vaccines. Influenza Vaccines come in two different types; one is a trivalent vaccine, and the other is a quadrivalent vaccine.
According to the influenza vaccine’s application, they are sub-classified into 2 major categories. One is the recombinant influenza vaccine which is available for the elderly and adults. The other one is available for children of 6 months or older age and is called a trivalent vaccine.
Due to these changes, the vaccines from the previous year become less effective or even ineffective because the outcomes of the virus vary each year. Fluoridation is the main reason for the market fluctuation for influenza vaccines.
The global influenza vaccination varies based upon several factors and the purpose of the end-user. The end-users of influenza vaccines market can be people from academic institutes, hospitals, clinics, organizations, researchers, and others.
In the forecasted period, the research sector is going to boost. It is driven by the dynamic and changing nature of the virus, which is mutating every year & consequently vaccines should be upgraded every six to twelve months.
Europe, America, the Middle East & Africa, and Asia-pacific are the four regions in which the influenza vaccine market is segmented. With the domination of more than half the population, America is pioneering the influenza vaccine market. The influenza virus infects 5% to 20% of the entire population, every year.
During the review period, European markets were the second-largest market for influenza vaccines. Influenza's generality, as well as increasing product demand, has boosted growth in the regional market. In 2019 there were 72% more vaccines taken from 68% in 2016 and 70% in 2017.
The forecasted period had shown exceptional growth in the Asia-Pacific. However, due to unavailability or difficulty of accessing treatment facilities the African and middle-east have the lowest growth rates. The Middle East and African countries are experiencing rapid growth in the influenza vaccines market because of the developing healthcare infrastructure.
In this report, we explore the influenza vaccines market size, share, and growth of influenza vaccines by analyzing the major players. Mergers, acquisitions, and other measures of business are among the different strategies adopted by different companies for expanding their businesses. Market participants generate revenue based on profit, sales, and the revenue generated by the market.
Influenza vaccines market are mainly distributed by the following companies:
GlaxoSmithKline PLC (UK)
Abbott Laboratories (US)
Mylan NV (US)
Hualan Biological Engineering Inc. (China)
Mitsubishi Tanabe Pharma (Japan)
Serum Institute of India Pvt. Ltd (India)
Several novel formulations have been examined recently. For older adults or people over 65 years of age, these formulations contain high doses of vaccines and other adjuvanted vaccines are MF59 AND AS03.
The efficiency of the vaccines has been boosted by these formulations. For older people, MF59 with the name Flaud has been qualified and licensed in over 25 countries and AS03 is a work in progress.
The Influenza Vaccines Market research report is made by drawing upon a thorough analysis of the vaccines and their various changes that are coming according to the virus spread and mutations. The report acts as a practical repository of the various aspects of the market, such as applications, end-users, regional sectors. And it showcases the need, reasons, and impacts of growth in various countries. As per the study analysis done to prepare this report, the Influenza vaccine market is supposed to achieve 5% growth by 2025. The insights of the report will help you picturise the growth of influenza vaccines market in a better way.
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Influenza Type, Manufacturing Technology, Vaccine Type and End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Abbott (U.S.), AstraZeneca (Europe), BioCryst Pharmaceuticals, Inc. (U.S.), Novartis AG (Europe), DAIICHI SANKYO COMPANY, LIMITED. (Asia Pacific), GlaxoSmithKline plc. (Europe). Hualan Biological Engineering Inc (Asia Pacific), Mitsubishi Tanabe Pharma Corporation (Asia Pacific), F. Hoffmann-La Roche Ltd (Europe), Sanofi (Europe), Paxvax Corporation (U.S.)|
|Key Market Opportunities||development of new vaccines and the improvement of the existing or current vaccines|
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
Influenza vaccine manufacturer takes five to six months approximately to for the first batch of the approved vaccines to become available.
A and B viruses are the causes of the seasonal flu and C typed causes milder respiratory symptoms.